HSP90AA1 and breast carcinoma: From a functional standpoint, HSP90 downregulation significantly blunted the growth inhibitory response of HER2+ breast cancer cell lines to single-agent and combined trastuzumab and docetaxel and abrogated their therapeutic cooperation.